A new editorial was recently published in Oncotarget’s Volume 15, on July 10, 2024, entitled, “The advances in targeting CD47/SIRPα “do not eat me” axis and their ongoing challenges as an anticancer therapy.”
Biopharma manufacturing ‘turbulence’ boosts inquiries for India-based providers, local CDMO execs say
India-based CDMOs have detected an uptick in biopharma client interest in their biologics and early-phase clinical offerings – and these manufacturers are accordingly adjusting their growth
March 28, 2024